News &amp; Updates

Cabozantinib demonstrates favourable risk–benefit profile in pretreated advanced HCC

Use of the vascular endothelial growth factor (VEGF) inhibitor cabozantinib in the second- or third-line treatment of patients with advanced hepatocellular carcinoma (HCC) appears to confer survival benefits without raising new safety concerns, according to the results of a phase II trial.

Cabozantinib demonstrates favourable risk–benefit profile in pretreated advanced HCC

Original New Drug Application Approvals by US FDA (01 - 15 February 2021)

New drug applications approved by US FDA as of 01-15 February 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 February 2021)

Less aggressive therapy reasonable in primary GI mantle cell lymphoma

15 Feb 2021

Primary gastrointestinal (GI) mantle cell lymphoma (MCL) is a rare disease with distinct presentations as compared to secondary GI MCL, a recent study has found. Patients with the primary malignancy tend to receive less aggressive treatment, but nevertheless achieve comparable clinical outcomes.

Less aggressive therapy reasonable in primary GI mantle cell lymphoma

15 Feb 2021

FOLFOX/XELOX improves survival, response rate in CRC patients with DDR-mutated tumour

Mutations affecting DNA damage response (DDR) are present in 22 percent of patients with metastatic colorectal cancer (CRC), reports a study. Initial treatment with fluoropyrimidine with oxaliplatin (FOLFOX/XELOX) improves overall survival in this population and is associated with a numerically higher response rate than fluoropyrimidine with irinotecan (FOLFIRI).

FOLFOX/XELOX improves survival, response rate in CRC patients with DDR-mutated tumour

Autologous stem cell transplant poses slight second malignancy risk to MM patients

Autologous stem cell transplant (aHSCT) seems to increase the risk of haematologic second primary malignancy (SPM) among multiple myeloma (MM) patients, though the absolute estimates were small, a recent has found.

Autologous stem cell transplant poses slight second malignancy risk to MM patients

Nodal positivity worsens survival in nonmetastatic renal cell carcinoma

11 Feb 2021

Pathologic nodal positivity (LN+) leads to worse survival outcomes in nonmetastatic renal cell carcinoma patients after curative nephrectomy, a recent study has found.

Nodal positivity worsens survival in nonmetastatic renal cell carcinoma

11 Feb 2021

Next-gen sequencing holds promise in gastric cancer

10 Feb 2021 by

Targeted next-generation sequencing is useful for identifying genomic alterations in patients with gastric cancer and, in turn, should aid patient stratification for treatment optimization, according to a Singapore study.

Next-gen sequencing holds promise in gastric cancer

Major drug–drug Interactions occur in hospitalized solid tumour cancer patients

A clinical pharmacy service that provides relevant pharmacotherapy consultations may be beneficial to hospitalized solid tumour cancer patients to prevent potentially serious concerns caused by moderate or major drug–drug interactions, suggests a recent study.

Major drug–drug Interactions occur in hospitalized solid tumour cancer patients

Breast density, not oestradiol, drives local platelet activation

The major determinant of local platelet activation is breast density and not oestradiol, a study has found, noting the potential of platelet inactivation as a therapeutic strategy for cancer prevention in postmenopausal women with dense breasts.

Breast density, not oestradiol, drives local platelet activation